Key result
Rotavirus vaccines demonstrate high efficacy and tolerability without increasing intussusception risk in infants.
Why the study?
Rotavirus gastroenteritis causes substantial morbidity and healthcare burden in children under 5 years, highlighting the need for an effective vaccine.
Do rotavirus vaccines provide high efficacy and tolerability without increased risk of intussusception in children younger than 5 years?
Do rotavirus vaccines provide high efficacy and tolerability without increased risk of intussusception in children younger than 5 years?
Rotavirus vaccines demonstrate high efficacy and safety, which will substantially reduce gastroenteritis-associated morbidity and healthcare utilization.
Answers are grounded in this paper and cite their sources.
May support rotavirus vaccination in infants; leaves open need for post-licensure surveillance in children under 5.
Rotavirus gastroenteritis primarily affects children younger than 5 years of age and is the leading cause of diarrhea-related hospitalizations worldwide. The substantial morbidity associated with this disease and the major burden on healthcare resources underscore the need for an effective vaccine. Two recently developed vaccines (RotaTeq [rotavirus vaccine, live, oral, pentavalent], and Rotarix [rotavirus vaccine, live]) share some characteristics of an ideal rotavirus vaccine. High efficacy, excellent tolerability, and no increased risk of intussusception were shown in separate clinical trials of more than 60,000 infants for each trial, as well as in smaller phase 3 clinical trials of each vaccine. Vaccination against rotavirus will substantially reduce rotavirus gastroenteritis-associated morbidity and mortality and, in so doing, bring about a significant reduction in rotavirus gastroenteritis-associated healthcare utilization.
No takes yet. Share an insight, caveat, or question.
Reisinger et al. (2008) conducted a review in Rotavirus gastroenteritis. Rotavirus vaccines (RotaTeq and Rotarix) was evaluated. Rotavirus vaccines RotaTeq and Rotarix demonstrated high efficacy, excellent tolerability, and no increased risk of intussusception in separate clinical trials of over 60,000 infants each.
Synapse has enriched 10 related papers. Consider them for comparative context: